These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 115074

  • 1. Development of acute dystonia and tardive dyskinesia in cebus monkeys.
    Bárány S, Ingvast A, Gunne LM.
    Res Commun Chem Pathol Pharmacol; 1979 Aug; 25(2):269-79. PubMed ID: 115074
    [Abstract] [Full Text] [Related]

  • 2. A monkey model of tardive dyskinesia (TD): evidence that reversible TD may turn into irreversible TD.
    Kovacic B, Domino EF.
    J Clin Psychopharmacol; 1982 Oct; 2(5):305-7. PubMed ID: 6890075
    [Abstract] [Full Text] [Related]

  • 3. Haloperidol-induced tardive dyskinesia in monkeys.
    Gunne LM, Bárány S.
    Psychopharmacology (Berl); 1976 Nov 24; 50(3):237-40. PubMed ID: 826968
    [Abstract] [Full Text] [Related]

  • 4. Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review.
    Domino EF.
    Psychopharmacology Suppl; 1985 Nov 24; 2():217-23. PubMed ID: 2860660
    [Abstract] [Full Text] [Related]

  • 5. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
    Rosengarten H, Bartoszyk GD, Quartermain D, Lin Y.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar 24; 30(2):273-9. PubMed ID: 16229932
    [Abstract] [Full Text] [Related]

  • 6. Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M, Chopra K, Kulkarni SK.
    Pharmacology; 2007 Mar 24; 79(3):171-83. PubMed ID: 17377417
    [Abstract] [Full Text] [Related]

  • 7. Application of a primate model for tardive dyskinesia.
    Bárány S, Häggström JE, Gunne LM.
    Acta Pharmacol Toxicol (Copenh); 1983 Feb 24; 52(2):86-9. PubMed ID: 6846025
    [Abstract] [Full Text] [Related]

  • 8. Effects of cannabinoid CB1 receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys.
    Madsen MV, Peacock LP, Werge T, Andersen MB, Andreasen JT.
    Neuropharmacology; 2011 Feb 24; 60(2-3):418-22. PubMed ID: 21029743
    [Abstract] [Full Text] [Related]

  • 9. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M, Chopra K, Kulkarni SK.
    Pharmacol Biochem Behav; 2008 Feb 24; 88(4):511-22. PubMed ID: 18022680
    [Abstract] [Full Text] [Related]

  • 10. A monitoring test for the liability of neuroleptic drugs to induce tardive dyskinesia.
    Gunne LM, Bárány S.
    Psychopharmacology (Berl); 1979 Jun 21; 63(3):195-8. PubMed ID: 39307
    [Abstract] [Full Text] [Related]

  • 11. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
    Rogoza RM, Fairfax DF, Henry P, N-Marandi S, Khan RF, Gupta SK, Mishra RK.
    Synapse; 2004 Dec 01; 54(3):156-63. PubMed ID: 15452862
    [Abstract] [Full Text] [Related]

  • 12. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
    Bishnoi M, Chopra K, Kulkarni SK.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug 01; 32(6):1473-8. PubMed ID: 18554768
    [Abstract] [Full Text] [Related]

  • 13. Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs.
    Lévesque C, Hernandez G, Mahmoudi S, Calon F, Gasparini F, Gomez-Mancilla B, Blanchet PJ, Lévesque D.
    Neuroscience; 2017 Oct 11; 361():43-57. PubMed ID: 28790021
    [Abstract] [Full Text] [Related]

  • 14. Effects of sulpiride on persistent neuroleptic-induced dyskinesia in monkeys.
    Häggström JE.
    Acta Psychiatr Scand Suppl; 1984 Oct 11; 311():103-8. PubMed ID: 6142586
    [Abstract] [Full Text] [Related]

  • 15. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
    Haleem DJ, Samad N, Haleem MA.
    Pharmacol Biochem Behav; 2007 May 11; 87(1):115-21. PubMed ID: 17498786
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological modification of experimental tardive dyskinesia.
    Bárány S, Gunne LM.
    Acta Pharmacol Toxicol (Copenh); 1979 Aug 11; 45(2):107-11. PubMed ID: 115227
    [Abstract] [Full Text] [Related]

  • 17. Tardive dyskinesia model in the common marmoset.
    Klintenberg R, Gunne L, Andrén PE.
    Mov Disord; 2002 Mar 11; 17(2):360-5. PubMed ID: 11921124
    [Abstract] [Full Text] [Related]

  • 18. Behavioral effects of 1-(m-chlorophenyl)piperazine (m-CPP) in a rat model of tardive dyskinesia.
    Samad N, Haleem MA, Haleem DJ.
    Pak J Pharm Sci; 2008 Jul 11; 21(3):262-8. PubMed ID: 18614422
    [Abstract] [Full Text] [Related]

  • 19. Hyperactive behavioural effects induced by intranigral infusion of a pyridinium metabolite of haloperidol in rats.
    Fang J.
    Can J Physiol Pharmacol; 1996 Dec 11; 74(12):1359-61. PubMed ID: 9047047
    [Abstract] [Full Text] [Related]

  • 20. Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic-induced dyskinesias.
    Häggström JE, Gunne LM, Carlsson A, Wikström H.
    J Neural Transm; 1983 Dec 11; 58(3-4):135-42. PubMed ID: 6663299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.